section name header

Pronunciation

GLYE-byoo-ride

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sulfonylureas

Indications

BEERS REMS, High Alert


Action

  • Lowers blood sugar by stimulating the release of insulin from the pancreas and increasing the sensitivity to insulin at receptor sites.
  • May also decrease hepatic glucose production.
Therapeutic effects:
  • Reduction in blood glucose.

Pharmacokinetics

Absorption: Well absorbed following oral administration; micronized forms have better absorption.

Distribution: Reaches high concentrations in bile and crosses the placenta.

Metabolism/Excretion: Mostly metabolized by the liver, primarily by the CYP2C9 isoenzyme.

Half-Life: 10 hr.

Time/Action Profile

(hypoglycemic activity)

ROUTEONSETPEAKDURATION
PO45–60 min1.5–3 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: photosensitivity, ERYTHEMA MULTIFORME, exfoliative dermatitis, rash

Endo: hypoglycemia

F and E: hyponatremia

GI: constipation, cramps, diarrhea, dyspepsia, hepatitis, nausea, vomiting

Hemat: agranulocytosis, APLASTIC ANEMIA, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia

Metab: appetite, weight

Neuro: dizziness, drowsiness, headache, weakness

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

DiaBeta, Glynase

Pill Image

glyburide_195-8610.jpg